Skip to main content
An official website of the United States government
Español
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Kepivance

(KEH-puh-vants)
A drug used to prevent and treat severe oral mucositis (mouth sores). It is used in patients with blood cancer who are being treated with high-dose chemotherapy and radiation therapy followed by an autologous stem cell transplant. It is also being studied in the prevention and treatment of common side effects in other types of cancer. Kepivance is a form of human keratinocyte growth factor that is made in the laboratory. It binds to certain receptors on the surface of cells in the lining of the mouth, stomach, and intestines. This may help protect healthy tissue from some of the side effects caused by certain types of cancer treatment. Kepivance is a type of cytoprotective agent. Also called palifermin.
Search NCI's Dictionary of Cancer Terms